ZOLL, now a part of Asahi Kasei Group Company, won the FDA’s premarket approval to market all of its external defibrillators in the U.S. These include the company’s R Series and X Series of monitors/defibrillators, as well as the AED Pro and AED Plus automated external defibrillators.
The R Series is intended for use inside of hospitals and clinics, while the X Series is designed for paramedics to use on-site or inside an ambulance. AED Pro is intended for professional rescuers to bring to sites of emergency, while the AED Plus is made for average folks to respond inside of airports, stadiums, and other facilities full of people. Both the AED Pro and AED Plus provide guidance on how to perform CPR, which is typically more frequently required than defibrillation. While the AED Pro provides a three lead ECG for basic monitoring, the AED Plus is fully automated and can be used by laymen.
All of the defibrillators feature Zoll’s Rectilinear Biphasic current waveform that aims to deliver the most current to difficult to defibrillate, high-impedance patients, as well as Real CPR Help, a technology to guide rescuers to perform optimal CPR.